This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. STUB downgraded, MNPR neutral, BETR.
Read original at benzingaStocks · News reference
8-K filing — Monopar Therapeutics (MNPR)
Filed: 2026-07-22 AccNo: 0001437749-26-024041 Size: 176 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Jul 22, 2026, 12:00 PM
- Checked
- Jul 22, 2026, 12:00 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128
Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $125 to $128.
Read original at benzingaCantor Fitzgerald Downgrades Monopar Therapeutics to Neutral, Raises Price Target to $119
Cantor Fitzgerald analyst Kristen Kluska downgrades Monopar Therapeutics (NASDAQ:MNPR) from Overweight to Neutral and raises the price target from $109 to $119.
Read original at benzingaBTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133
BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $117 to $133.
Read original at benzinga